Sponsored by:

headline-text-20005

Erik L. Ridley
Nov 24, 2000
Ge12 17 99 small
body-text-20005
Latest in Nuclear Medicine
Manufacturing Facility Process
Eckert & Ziegler signs manufacturing deal with Pentixapharm
April 24, 2025
Murr
UM launches new research reactor with $10M deal
April 23, 2025
Imaging Life Issue 20 now available
Sponsored
Imaging Life Issue 20 now available
April 1, 2025
Alzheimers Tau
Having a father with Alzheimer's could mean higher risk of the disease
April 9, 2025
Related Stories
Dementiasmall
Nuclear Medicine
FDG-PET clears up metabolic murkiness between dementia and Alzheimer's
Gammasmall07 19 00 rn
Nuclear Medicine
Gamma Medica sees better lymph node imaging with handheld probe
Y 364small
Nuclear Medicine
Nuclear medicine researchers seek better prostate imaging with new gamma probe
Imaging Life Issue 20 now available
Sponsor Content
Imaging Life Issue 20 now available
More in Nuclear Medicine
Eckert & Ziegler signs manufacturing deal with Pentixapharm
By AuntMinnie.com staff writers
Eckert & Ziegler Radiopharma GmbH has signed a manufacturing agreement with Pentixapharm.
April 24, 2025
Manufacturing Facility Process
UM launches new research reactor with $10M deal
By AuntMinnie.com staff writers
The University of Missouri (UM) has inked a $10 million deal with a Korean consortium.
April 23, 2025
Murr
Shine Technologies, Modawina Medical sign UAE distribution deal
By AuntMinnie.com staff writers
Shine Technologies has signed an agreement with Modawina Medical Company to distribute Shine’s lutetium-177 isotope in the UAE.
April 22, 2025
Atom Nuclear Lab 400
Having a father with Alzheimer's could mean higher risk of the disease
By Kate Madden Yee
Having a father with Alzheimer's may be tied to a greater spread of the tau protein in the brain, researchers have reported.
April 9, 2025
Alzheimers Tau
China limits exports of rare earth elements, targets CT x-ray tubes
By Erik L. Ridley
China's Ministry of Commerce has announced export controls for several rare earth elements and launched investigations of imported CT x-ray tubes.
April 4, 2025
China Flag
IAEA touts radionuclide development activities
By Will Morton
The IAEA has highlighted its worldwide activities to meet increasing demands for alpha-emitting radionuclides for use in Targeted Alpha Therapy.
March 18, 2025
Isotopes1
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
How effective is Pluvicto in a ‘real-world’ setting?
By Will Morton
Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.
September 20, 2024
Prostate
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
Page 1 of 437
Next Page